WSTAM
ACOR

Wilbanks Smith & Thomas Asset Management’s Acorda Therapeutics ACOR Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed -$2K – 1400
2018
Q3 		$2K Buy
+1
New +$3.1K ﹤0.01% 1454

Other funds holding ACOR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's ACOR Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Acorda Therapeutics (ACOR) in Q4 2018, closing a stake of 1 share — an estimated $2K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in ACOR in Q3 2018 and held it in 1 quarter. The position peaked at $2K in Q3 2018. 179 funds tracked by Wall St. Rank hold ACOR as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Acorda Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 1 Acorda Therapeutics share in Q4 2018, an estimated $2K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Acorda Therapeutics in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Acorda Therapeutics position peaked at $2K in Q3 2018.
  • 179 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.